| |
Myobloc for Hyperhidrosis :: Publications
Myobloc was approved for the use in cervical dystonia in Dec 2000. Currently most of the publications regarding Myobloc discuss its use for neurologic indications, however, there are many publications regarding the use of Myobloc for facial wrinkles and hyperhidrosis that are currently being written/ and or submitted. We will update this information as it becomes available.
References for more information include:
- MYOBLOC Prescribing Information, San Diego, CA: Elan Pharmaceuticals.
- Seminars in Cutaneous Medicine and Surgery. 2001;Vol. 20, No. 2:127-136.
- Setler P: The biochemistry of botulism toxin type B. Neurology 55:S22, 2000.
- Setler P. The biochemistry of botulinum toxin type B. Neurology. 2000;55(suppl 5):S22-S28.
- Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of Neurobloc (botulinum toxin type B) in type A-resistant
cervical dystonia. Neurology. 1999;53:1431-1438.
- Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of Neurobloc (botulinum toxin type B) in type A-responsive
cervical dystonia. Neurology. 1999;53:1439-1446
- Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and
efficacy study in cervical dystonia. Neurology. 1997;49:701-707.
- Moyer E, Setler PE. Botulinum toxin type B: experimental and clinical experience. In: Jankovic J, Hallett M, eds.
Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:71-85.
- Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology.
- Scott A: Clostridial toxins as therapeutic agents, in Simpson LL (ed.): Botulinum Neurotoxin and Tetanus Toxin. New York, Academic Press, 1989; 399-412.
- Data on file, Elan Pharmaceuticals.
|
|
